Niagen Bioscience, Inc. (NAGE) as of March 31, 2026 presents a net-positive liquidation posture—uncommon for a company with $158.2 million in accumulated deficit—driven by a cash-heavy balance sheet and a liability stack that is modest relative to total assets. Total assets are $114.3 million against total liabilities of $32.0 million, yielding reported book equity of $82.3 million. Under liquidation haircuts, the recovery picture is as follows: cash and equivalents of $66.5 million (including $152K restricted) recovers near par; accounts receivable of $13.1 million (net of $176K current allowance) recovers at 90-95%, or approximately $11.8-12.4 million; inventory of $24.0 million (gross, no reserve recorded) recovers at roughly 60%, or $14.4 million—subject to the caveat that $13.5 million is raw materials (NRC), whose liquidation value depends heavily on the sole-supplier relationship with W.R. Grace and limited alternative buyers; PP&E of $1.3 million recovers at 50-70%, or $0.6-0.9 million; intangibles of $5.5 million (primarily licensed patent rights) recover at effectively zero under liquidation. Total haircut asset recovery approximates $95-97 million before liabilities. Liability stack at face value includes current liabilities of $22.8 million (accounts payable $13.3 million, accrued liabilities $7.6 million, current operating lease $1.0 million, deferred compensation current $0.5 million) and non-current liabilities of $9.2 million (deferred compensation non-current $5.1 million, operating lease non-current $1.5 million, deferred revenue non-current $2.6 million). Critically, the MD&A discloses off-balance-sheet obligations material to a liquidation analysis: $18.5 million in inventory purchase commitments (unconditional, would not extinguish on windup) and $9.5 million plus GBP 0.4 million in fixed deferred consideration payable through 2038 for assigned patent rights—these are not separately XBRL-tagged as distinct liability line items in the balance sheet but are disclosed in the liquidity section. Net equity recovery under this lens approximates $65-70 million before contingent litigation exposure (Elysium Health litigation disclosed but damages not quantified in this filing) and purchase commitment wind-down costs. A $20.0 million share repurchase program authorization was expanded in March 2026 and $2.4 million was deployed in Q1 2026, modestly reducing the cash buffer. The February 2026 divestiture of the Analytical Reference Standards and Services segment for $5.8 million gross proceeds improved liquidity and reduced segment operating drag. Full valuation allowance maintained on all deferred tax assets.
▼ Community Notes